Stomach Cancer Drugs Market

Stomach Cancer Drugs Market - Size, Share,
Growth, Outlook, and Opportunity Analysis,
2018-2026
Stomach cancer is the fifth most common cancer globally regardless of gender as reported by the
World Cancer Research Fund (WCRF) in 2018. There are many factors which cause stomach cancer
such as unhealthy diet, smoking, obesity, alcohol, and Helicobacter pylori infection. According to the
Cancer Research U.K. data of 2016, one out of three stomach cancer cases is related to
Helicobacter pylori infection in the U.K. annually. Stomach cancer tests identify the stage of the
cancer and the patient is treated accordingly. Targeted drug therapies are frequently used to treat
stomach cancer as these drugs target the rapidly dividing cells and have less side effects. Drugs that
target HER2 are under developmental studies to treat advanced stomach cancer. For instance,
pertuzumab in combination with trastuzumab and chemotherapy is under phase 3 clinical trials to
treat metastatic gastroesophageal junction or gastric cancer.
Request Sample Copy of Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/2667
Stomach cancer, is a buildup of abnormal cells that form a mass in part of the stomach. Symptoms of
stomach cancer include fatigue, feeling bloated after eating, severe heartburn, severe indigestion,
persistent nausea, stomach pain, persistent vomiting, and unintentional weight loss. There are many
treatments available for stomach cancer such as targeted drug therapy, chemotherapy,
immunotherapy etc. Stomach cancer drugs are also used in combinations to increase their
effectiveness to fight stomach cancer. For instance, TPF is a combination of drugs which include
Docetaxel (Taxotere), Cisplatin (Platinol), and Fluorouracil, which is used to kill cancer cells in
different ways.
Increasing FDA approvals of biosimilars for treatment of stomach cancer is expected
to drive growth of the stomach cancer drugs market
The stomach cancer drugs market revenue is expected to increase, owing to increasing number
of FDA approvals for biosimilars. Adoption of biosimilars in last five years is on a high demand
because of the comparatively lower price than biologics treatment of stomach cancer. For
instance, in 2017 Biocon Ltd., in partnership with Mylan N.V., received FDA approval for Ogivri
(trastuzumab) for the treatment of stomach cancer or gastro-esophageal junction
adenocarcinoma. Ogivri is the first FDA-approved biosimilar of Herceptin and the first biosimilar
from Mylan and Biocon’s joint portfolio approved in the U.S. Further, In March 2019, Pfizer Inc.
announced the U.S. Food and Drug Administration (FDA) approval of TRAZIMERA (trastuzumab),
a biosimilar of Herceptin (trastuzumab), for the treatment of HER2 overexpressing metastatic
gastric or gastroesophageal junction adenocarcinoma.
Report includes chapters which deeply display the following deliverable about industry :
• Stomach Cancer Drugs Market Research Objective and Assumption
• Stomach Cancer Drugs Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Stomach Cancer Drugs Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value
Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Stomach Cancer Drugs Market, By Regions
• Stomach Cancer Drugs Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Stomach Cancer Drugs Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Stomach Cancer Drugs Market Manufacturing Cost Analysis including Key Raw Materials and Key
Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning
and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Stomach Cancer Drugs Market Forecast including Production, Consumption, Import and Export
Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Stomach Cancer Drugs Market - Competitive Landscape
Key players operating in the global stomach cancer drugs market include Pfizer Inc.,
Eli Lilly and Company, GlaxoSmithKline Plc., Kuhnil Pharmaceutical Co. Ltd., Daiichi
Sankyo Co. Ltd., Merck KGaA, AstraZeneca Plc, Otsuka Holdings Co. Ltd., Sanofi S.A.,
and F. Hoffmann-La Roche Ltd, Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb
(BMS), Jiangsu HengRui Medicine Co. Ltd., Gilead Science Inc., Celgene Corporation,
Taiho Pharmaceutical, Boston Biomedical Inc., and Merck & Co.
Inquire Here Before Purchase:
https://www.coherentmarketinsights.com/insight/talk-to-analyst/2667
Detailed Segmentation:
• Global Stomach Cancer Drugs Market, By Therapy Type:
• Kinase Inhibitors
• Nucleoside Metabolic Inhibitors
• Anthracyclines
• Microtubule Inhibitors
• VEGF Antibodies
• HER2 Receptor Antagonists
• Car T Cell Therapy
• Global Stomach Cancer Drugs Market, By Application:
• Adenocarcinomas
• Gastrointestinal Stromal Tumors
• Carcinoid Tumors
• Global Stomach cancer drugs Market, By Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Global Stomach cancer drugs Market, By Region:
• North America
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Download Report